Clinical Trial: An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer

U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT06883552) titled 'An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer' on March 13.

Brief Summary: This is a single-arm study evaluating the efficacy and safety of Stapokibart Injection in combination with Tislelizumab Injection in patients with driver gene-negative NSCLC who have failed prior PD-1/PD-L1 inhibitor therapy.

Study Start Date: Oct. 01, 2025

Study Type: INTERVENTIONAL

Condition: Lung Cancer (NSCLC)

Intervention: DRUG: Tislelizumab Injection

During treatment cycles 1-18, Tislelizumab Injection will be administered in combination wi...